BMGLHealthcare · Medical Care FacilitiesBMGL Stock Forecast: Basel Medical Group Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 1 Aug 2026 — in the weakest quartile.
BMGL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Basel Medical Group Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Basel Medical Group Ltd. — and when they’d sell — is the membership.
BMGL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BMGL, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BMGL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Basel Medical Group Ltd. (BMGL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 115.0×
- Price / sales
- 0.6×
- Price / book
- 1.8×
- EV / EBITDA
- −2.6×
Cheaper than 6% of US stocks
Cheaper than 80% of US stocks
Cheaper than 48% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- 67.1%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −32.8%
- Net margin
- −68.2%
Higher than 91% of US stocks
Higher than 20% of US stocks
Higher than 8% of US stocks
- Return on equity
- −147.4%
- Return on assets
- −15.5%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BMGL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMGL appears on the weeks it earns a place.
Frequently asked questions about BMGL stock
How does Ticker Nerd's model rank BMGL?
As at 1 Aug 2026, Basel Medical Group Ltd. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
What is the BMGL stock forecast for 2030?
No analyst covering Basel Medical Group Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMGL are extrapolating price history, which says nothing about the business.
What does Basel Medical Group Ltd. do?
Basel Medical Group Ltd is a Singapore-based healthcare provider specializing in orthopedic, trauma, and sports medicine services. The company offers general and subspecialized orthopedic care including knee and hip replacements, spine surgery, foot and ankle procedures, and minimally invasive orthopedic treatments, alongside neurosurgical services.
About Basel Medical Group Ltd.
Basel Medical Group Ltd is a Singapore-based healthcare provider specializing in orthopedic, trauma, and sports medicine services. The company offers general and subspecialized orthopedic care including knee and hip replacements, spine surgery, foot and ankle procedures, and minimally invasive orthopedic treatments, alongside neurosurgical services. Basel Medical operates a network of clinics across Singapore and provides consultation, medical diagnosis, surgical treatments, physiotherapy, and related services for orthopedic and neurological conditions. Beyond clinical services, the company serves corporate clients in construction, marine, and oil and gas industries through occupational health and executive health screening programs. The company also expanded its service offerings through the acquisition of Bethesda Medical, adding diagnostic imaging, outpatient care, and mental health services to its portfolio. Additionally, Basel Medical holds contracts for healthcare product supply in the Asia-Pacific region and is integrating AI-powered technologies into its healthcare supply chain operations to enhance logistics and service delivery.
CEO Dr. Yen Feng Chhoa M.D. · 82 employees · Singapore · https://baselmedical.com